The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Ibrutinib tablets, in the strengths of 140 mg, 280 mg, 420 mg and 560 mg, Zydus Cadila said in a statement.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3znaL4K
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Zydus Cadila gets tentative nod from USFDA to market cancer drug
https://ift.tt/eA8V8J
No comments:
Post a Comment